What is a stock summary page? Click here for an overview.
Business Description
Galmed Pharmaceuticals Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011313900
Description
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 418.05 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 49.8 | |||||
| 3-Year EPS without NRI Growth Rate | 49.9 | |||||
| 3-Year FCF Growth Rate | 50.8 | |||||
| 3-Year Book Growth Rate | -55.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 64.97 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.54 | |||||
| 9-Day RSI | 35.53 | |||||
| 14-Day RSI | 37.77 | |||||
| 3-1 Month Momentum % | -14.14 | |||||
| 6-1 Month Momentum % | -63.19 | |||||
| 12-1 Month Momentum % | -32.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.03 | |||||
| Quick Ratio | 7.03 | |||||
| Cash Ratio | 6.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -52.7 | |||||
| Shareholder Yield % | 5.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -43.67 | |||||
| ROA % | -38.06 | |||||
| ROIC % | -195.97 | |||||
| 3-Year ROIIC % | 661.95 | |||||
| ROC (Joel Greenblatt) % | -4523.33 | |||||
| ROCE % | -46.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.14 | |||||
| Price-to-Tangible-Book | 0.14 | |||||
| EV-to-EBIT | 1.43 | |||||
| EV-to-EBITDA | 1.45 | |||||
| EV-to-FCF | 1.92 | |||||
| Price-to-Net-Current-Asset-Value | 0.17 | |||||
| Price-to-Net-Cash | 0.18 | |||||
| Earnings Yield (Greenblatt) % | 69.93 | |||||
| FCF Yield % | -166.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLMD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galmed Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -37.435 | ||
| Beta | -0.09 | ||
| 3-Year Sharpe Ratio | -0.75 | ||
| 3-Year Sortino Ratio | -1.02 | ||
| Volatility % | 129.22 | ||
| 14-Day RSI | 37.77 | ||
| 14-Day ATR ($) | 0.336632 | ||
| 20-Day SMA ($) | 2.03102 | ||
| 12-1 Month Momentum % | -32.07 | ||
| 52-Week Range ($) | 1.67 - 23.8 | ||
| Shares Outstanding (Mil) | 1.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galmed Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galmed Pharmaceuticals Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Galmed Pharmaceuticals Ltd Frequently Asked Questions
What is Galmed Pharmaceuticals Ltd(GLMD)'s stock price today?
The current price of GLMD is $1.74. The 52 week high of GLMD is $23.80 and 52 week low is $1.67.
When is next earnings date of Galmed Pharmaceuticals Ltd(GLMD)?
The next earnings date of Galmed Pharmaceuticals Ltd(GLMD) is 2025-05-30 Est..
Does Galmed Pharmaceuticals Ltd(GLMD) pay dividends? If so, how much?
Galmed Pharmaceuticals Ltd(GLMD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers